San Ramon, Calif., and Nieuwegein, The Netherlands, November 21, 2016 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use in the Netherlands of its closed-chest Revivent TC™ TransCatheter Ventricular Enhancement System. The Less Invasive Ventricular Enhancement™ or LIVE™ procedure was performed by cardiothoracic surgeon Dr. Patrick Klein, MD and by interventional cardiologist Dr. Pierfrancesco Agostoni, MD at the St. Antonius Hospital in Nieuwegein, The Netherlands.

SAN RAMON, Calif., October 4, 2016 — BioVentrix, Inc., a pioneer of technologies and procedures for less-invasive treatment of heart failure, today announced that current Board member Steven Healy has been appointed to the position of Chairman of the Board of Directors.

The Revivent TC™ TransCatheter Ventricular Enhancement System enables the treatment and management of patients who suffered a myocardial infarction resulting in left ventricular dysfunction.

SAN RAMON, Calif., June 27, 2016– BioVentrix Inc., an emerging medical device company dedicated to the minimally invasive treatment of heart failure (HF), announced today that it has received certification for CE marking its Revivent TC™ TransCatheter Ventricular Enhancement System. Following a myocardial infarction or heart attack, the Revivent TC™ System implants proprietary micro-anchor pairs to exclude scarred myocardium from the healthy tissue of the left ventricle (LV). The restoration of the LV to a more optimal volume and conical shape has proven to enhance cardiac performance and significantly improve a patient’s quality of life¹.

SAN RAMON, Calif., May 31, 2016 – BioVentrix Inc., an emerging medical device company for less invasive treatment of heart failure (HF), today announced that it has received a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial, named ALIVE (American Less Invasive Ventricular Enhancement). The trial is designed to demonstrate the safety and effectiveness of the Revivent TC™ TransCatheter Ventricular Enhancement System; a hybrid closed-chest transcatheter procedure to treat patients suffering from ischemic cardiomyopathy by reshaping and restoring the left ventricle (LV). This is accomplished by implanting micro-anchoring pairs in the LV to exclude scarred myocardium from the healthy tissue.